
Adult Immunization
Latest News

Home Sleep Testing for GLP-1 Coverage Shows Modest Diagnostic Yield in New Study

FDA Expands Teplizumab Approval for Pediatric Stage 3 Type 1 Diabetes

Reishi Mushroom Extract Outperformed Melatonin for Chronic Insomnia in New Study

Prenatal Sleep Expectations Predict Postpartum Sleep Quality, Study Finds

Rural Patients at High Risk for Sleep Apnea Less Likely to Be Referred for Evaluation: SLEEP 2026

Shorts










Latest Videos
All News

The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.

AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant Adults
AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Takeda reported phase 3 data showing zasocitinib achieved higher week 16 PASI 100 responses than deucravacitinib in plaque psoriasis.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

New FLOW trial data presented at ERA 2026 showed semaglutide improved health-related quality of life in adults with type 2 diabetes and CKD.

Recent FDA updates include new actions in diabetes, hypertension, chronic HDV infection, bipolar depression, and CKD in type 1 diabetes.


















































































































































































